Media Search News 03.28.22 FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) Continue Reading 03.04.22 Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022 Continue Reading 02.28.22 Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results Continue Reading 02.15.22 Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases Continue Reading 01.19.22 UCB to acquire Zogenix Continue Reading 05.14.12 Zogenix Reports First Quarter 2012 Financial Results Continue Reading 05.03.12 Zogenix Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results Continue Reading 05.02.12 Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro(TM) for Treatment of Chronic Pain Continue Reading 03.29.12 Zogenix and Battelle Ink Marketing Agreement for DosePro(R) Drug Delivery Technology Continue Reading 03.08.12 Zogenix Reports Fourth Quarter and Full Year 2011 Financial Results Continue Reading 02.27.12 Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2011 Financial Results Continue Reading 02.10.12 Zogenix to Present at Leerink Swann 2012 Global Healthcare Conference Continue Reading 01.25.12 Zogenix and Battelle to Collaborate on Advanced Drug Delivery Technology Continue Reading 12.21.11 Zogenix Reviews Positive Sales Trends and 2012 Commercial Initiatives for SUMAVEL(R) DosePro(R) Continue Reading 12.21.11 Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective March 31, 2012 Continue Reading 12.20.11 Zogenix Completes Zohydro(TM) Pre-NDA Meetings With FDA Continue Reading 11.21.11 Zogenix to Present at Two Upcoming Conferences Continue Reading 11.10.11 Zogenix Reports Third Quarter 2011 Financial Results Continue Reading 11.04.11 Zogenix Announces Conference Call and Webcast to Present Third Quarter 2011 Financial Results Continue Reading 10.12.11 Zogenix to Host Investor Meeting on October 13, 2011 Continue Reading 09.30.11 Zogenix Achieves Zohydro(TM) Long-Term Safety Database for NDA Continue Reading 09.19.11 Zogenix to Present at UBS 2011 Global Life Sciences Conference Continue Reading 09.16.11 Zogenix Prices Public Offering of Common Stock Continue Reading 08.24.11 Zogenix Files Registration Statement for Proposed Follow-On Offering Continue Reading 08.17.11 Zogenix Reports Positive Phase 3 Results for Zohydro -- Meets Primary Efficacy Endpoint Continue Reading 08.16.11 Zogenix to Hold Conference Call to Discuss Pivotal Phase 3 Results for Zohydro for Treatment of Chronic Pain Continue Reading 08.10.11 Zogenix Reports Second Quarter 2011 Financial Results Continue Reading 08.04.11 Zogenix Announces Publication of SUMAVEL(R) DosePro(R) Phase 4 Clinical Data Continue Reading 08.02.11 Zogenix Announces 2011 Second Quarter Conference Call and Webcast Continue Reading 07.18.11 Zogenix Closes $30 Million Royalty Financing With Cowen Healthcare Royalty Partners II Continue Reading 07.12.11 Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro(R) Delivery System and DURECT's SABER(TM) Depot Technology Continue Reading 06.30.11 Zogenix Enters $30 Million Royalty Financing Agreement With Cowen Healthcare Royalty Partners II Continue Reading 06.13.11 Zogenix to Present at 2011 Wells Fargo Securities Healthcare Conference Continue Reading 06.06.11 Fast-Acting Migraine Treatment Highlighted During National Migraine Awareness Month Continue Reading 05.27.11 Zogenix to Present Additional SUMAVEL(R) DosePro(R) Phase 4 Results at Headache Meetings in June Continue Reading 05.25.11 Zogenix Stockholders Elect Mark Wiggins to Board of Directors Continue Reading 05.18.11 Zogenix Highlights DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference Continue Reading 05.16.11 Zogenix Reports First Quarter 2011 Financial Results Continue Reading 05.11.11 Zogenix to Highlight DosePro(R) Needle-Free Delivery System at 2011 AAPS National Biotechnology Conference Continue Reading 05.04.11 Zogenix to Hold Conference Call to Discuss First Quarter 2011 Financial Results Continue Reading 04.13.11 Zogenix Demonstrates Increased Overall Patient Satisfaction With SUMAVEL(R) DosePro(R) Over Multiple Migraine Attacks Continue Reading 04.12.11 Zogenix Announces SUMAVEL(R) DosePro(R) Named Patient Program Continue Reading 03.16.11 Zogenix Announces Extension of SUMAVEL(R) DosePro(TM) U.S. Patent Protection by Eight Years Continue Reading 03.03.11 Zogenix Reports Fourth Quarter and Full Year 2010 Financial Results Continue Reading 03.01.11 Zogenix to Present SUMAVEL(R) DosePro(TM) Phase 4 Results at American Academy of Neurology Continue Reading 02.16.11 Zogenix to Hold Conference Call to Discuss Fourth Quarter and Full Year 2010 Financial Results Continue Reading 02.10.11 Zogenix Announces Completion of Enrollment in ZX002 Phase 3 Efficacy Study Continue Reading 02.09.11 Zogenix Receives 2011 Drug Delivery Partnerships Innovation Award for SUMAVEL(R) DosePro(TM) Continue Reading 02.08.11 Zogenix to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference Continue Reading 01.06.11 Zogenix and Desitin Announce Marketing Approval for SUMAVEL(R) DosePro(TM) in Germany and the United Kingdom Continue Reading 12.23.10 Zogenix Announces Partial Exercise of Over-Allotment Option for Initial Public Offering Continue Reading 12.13.10 Zogenix Receives 2010 Most Innovative Product Award for SUMAVEL(R) DosePro(TM) Continue Reading 12.02.10 Zogenix and Desitin Announce First European Marketing Approval for SUMAVEL(R) DosePro(TM) Continue Reading 11.30.10 Zogenix Announces Completion of Enrollment in ZX002 Phase 3 12-Month Safety Study Continue Reading 11.22.10 Zogenix Announces Pricing of Initial Public Offering Continue Reading 09.07.10 Zogenix Files Registration Statement for Proposed Initial Public Offering Continue Reading 07.13.10 Zogenix Secures $35 Million Debt Facility And Raises $15 Million Investment Capital Continue Reading 03.17.10 Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone Continue Reading 03.01.10 ZOGENIX APPOINTS NEW CHIEF FINANCIAL OFFICER Continue Reading 01.13.10 SUMAVEL™ DosePro™ Available in the United States to Treat Acute Migraine and Cluster Headaches Continue Reading 12.07.09 Zogenix Increases Series B Preferred Stock Financing to $71 Million, Raising $35 Million in Second Tranche Continue Reading 10.28.09 Zogenix and Desitin Filing for European Regulatory Approval of SUMAVEL DosePro Continue Reading 10.22.09 Zogenix and Astellas Announce Data Published Showing the Benefits of SUMAVEL DosePro Needle-Free Delivery System Continue Reading 09.23.09 Zogenix Closes $51 million in Series B Preferred Stock Financing and Prepares for January 2010 Launch Of SUMAVEL™ DosePro™ Continue Reading 08.03.09 Zogenix and Astellas Enter Exclusive Co-Promotion Agreement in the US for Newly Approved Sumavel DosePro Continue Reading 07.16.09 Sumavel™ DosePro™ (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache Continue Reading 02.18.09 Zogenix Reports FDA Provides New PDUFA Date for Sumavel™ DosePro™ Continue Reading 07.25.08 Zogenix Closes $18 Million Financing with Oxford Finance Corporation and CIT Healthcare LLC Continue Reading 06.28.08 Zogenix Announces Clinical Study Results for sumatriptan DosePro™, a Novel Migraine Treatment Continue Reading 04.17.08 Zogenix Completes Management Team with Cynthia Robinson, Ph.D., CDO, & Mark Thompson, VP, Sales & Managed Markets Continue Reading 03.24.08 Zogenix, Inc. Files Registration Statement for Proposed Initial Public Offering Continue Reading 03.19.08 Zogenix Announces sumatriptan DosePro™ NDA Accepted for Filing by FDA Continue Reading 03.17.08 Zogenix Licenses European Development and Commercial Rights for sumatriptan DosePro™ to Desitin Pharmaceuticals, GmbH Continue Reading 01.09.08 Zogenix Raises $18 Million in Preferred Stock Financing Continue Reading 11.27.07 Zogenix Licenses Exclusive U.S. Commercial Rights for Late Stage, Controlled-Release, Opioid Product from Elan Continue Reading 06.07.07 Zogenix Appoints David Nassif Executive Vice President and Chief Financial Officer Continue Reading 03.19.07 Zogenix Closes $10 Million Deal with GE Healthcare Financial Services Continue Reading Load More Posts